Cancer remains one of the leading causes of morbidity and mortality worldwide, despite significant advances in molecular biology, targeted therapy, and ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

The FDA cleared a second arm for enrollment in the trial after one NSCLC patient demonstrated a complete response to the non-boosted therapy.

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...

Overall survival (OS) in refractory metastatic colorectal cancer (mCRC) improved significantly with the addition of the VEGF ...

High-grade astrocytoma, which includes glioblastoma, is a fast-growing, aggressive brain cancer that often returns after the tumor is removed, making it difficult to treat. Patients with recurrent ...

Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent ...

HHS states it was cleaning up "dated content." But advocates for people with autism say the warnings are still needed.

The Department of Health and Human Services quietly removed an advisory on its website warning users against deceptive ...

Advancements in early detection and multimodal treatment strategies have significantly improved survival rates for early-stage breast cancer, now exceeding 80% at 10 years. However, breast cancer ...